Zacks Research Brokers Increase Earnings Estimates for MMSI

Merit Medical Systems, Inc. (NASDAQ:MMSI) – Equities researchers at Zacks Research increased their FY2024 EPS estimates for Merit Medical Systems in a report issued on Wednesday, November 20th. Zacks Research analyst I. Bandyopadhyay now forecasts that the medical instruments supplier will earn $3.36 per share for the year, up from their prior estimate of $3.31. The consensus estimate for Merit Medical Systems’ current full-year earnings is $3.36 per share. Zacks Research also issued estimates for Merit Medical Systems’ Q3 2025 earnings at $0.93 EPS, Q4 2025 earnings at $0.98 EPS, FY2025 earnings at $3.70 EPS and FY2026 earnings at $4.07 EPS.

Merit Medical Systems (NASDAQ:MMSI) last issued its quarterly earnings results on Wednesday, October 30th. The medical instruments supplier reported $0.86 EPS for the quarter, beating the consensus estimate of $0.80 by $0.06. Merit Medical Systems had a net margin of 9.05% and a return on equity of 15.61%. The business had revenue of $339.85 million during the quarter, compared to the consensus estimate of $334.60 million. During the same quarter in the prior year, the firm earned $0.75 EPS. The firm’s quarterly revenue was up 7.8% on a year-over-year basis.

A number of other equities research analysts have also commented on MMSI. Needham & Company LLC restated a “buy” rating and set a $109.00 price objective on shares of Merit Medical Systems in a research report on Thursday, October 31st. Wells Fargo & Company increased their target price on shares of Merit Medical Systems from $85.00 to $103.00 and gave the stock an “equal weight” rating in a research report on Monday, September 16th. StockNews.com cut shares of Merit Medical Systems from a “buy” rating to a “hold” rating in a report on Sunday, November 3rd. Robert W. Baird increased their price objective on Merit Medical Systems from $107.00 to $109.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. Finally, Bank of America boosted their target price on Merit Medical Systems from $92.00 to $103.00 and gave the company a “neutral” rating in a research note on Monday, September 16th. Three investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Merit Medical Systems has a consensus rating of “Moderate Buy” and a consensus target price of $103.36.

Merit Medical Systems Stock Performance

Shares of Merit Medical Systems stock opened at $105.03 on Friday. Merit Medical Systems has a 12 month low of $65.46 and a 12 month high of $105.46. The company has a quick ratio of 3.82, a current ratio of 5.36 and a debt-to-equity ratio of 0.57. The stock has a market cap of $6.12 billion, a PE ratio of 51.49, a price-to-earnings-growth ratio of 2.60 and a beta of 0.89. The business has a fifty day simple moving average of $98.23 and a 200-day simple moving average of $90.55.

Insider Activity at Merit Medical Systems

In related news, Director F. Ann Millner sold 12,500 shares of Merit Medical Systems stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $101.55, for a total transaction of $1,269,375.00. Following the sale, the director now directly owns 32,391 shares of the company’s stock, valued at $3,289,306.05. This trade represents a 27.85 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Raul Jr. Parra sold 29,646 shares of the company’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $98.02, for a total value of $2,905,900.92. Following the completion of the transaction, the chief financial officer now directly owns 16,361 shares of the company’s stock, valued at approximately $1,603,705.22. This trade represents a 64.44 % decrease in their position. The disclosure for this sale can be found here. 3.70% of the stock is owned by corporate insiders.

Institutional Trading of Merit Medical Systems

Several institutional investors have recently modified their holdings of the company. American Century Companies Inc. boosted its position in shares of Merit Medical Systems by 2.9% during the 2nd quarter. American Century Companies Inc. now owns 4,216 shares of the medical instruments supplier’s stock valued at $362,000 after acquiring an additional 118 shares in the last quarter. Xponance Inc. boosted its holdings in Merit Medical Systems by 4.9% during the second quarter. Xponance Inc. now owns 3,621 shares of the medical instruments supplier’s stock valued at $311,000 after purchasing an additional 170 shares in the last quarter. Glenmede Trust Co. NA grew its stake in shares of Merit Medical Systems by 0.6% in the 3rd quarter. Glenmede Trust Co. NA now owns 28,637 shares of the medical instruments supplier’s stock valued at $2,830,000 after purchasing an additional 170 shares during the period. Captrust Financial Advisors grew its stake in shares of Merit Medical Systems by 2.6% in the 3rd quarter. Captrust Financial Advisors now owns 7,440 shares of the medical instruments supplier’s stock valued at $735,000 after purchasing an additional 187 shares during the period. Finally, TD Private Client Wealth LLC raised its holdings in shares of Merit Medical Systems by 13.9% in the 3rd quarter. TD Private Client Wealth LLC now owns 1,732 shares of the medical instruments supplier’s stock worth $171,000 after buying an additional 211 shares in the last quarter. Institutional investors and hedge funds own 99.66% of the company’s stock.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.